Volunteers have been vying for participation in the human trials of the Covid-19 vaccine at AIIMS. On Saturday evening, after the approval of the trial from the AIIMS Ethics Committee, the hospital made a small appeal to become volunteers. After this, within the next few hours, more than a thousand people have contacted AIIMS. While in AIIMS, only 100 people can be included in this phase one trial. The trial is expected to begin in the next two to three days.
The number released to become volunteers
Dr. Sanjay Rai, Principal Investigator of the COVID Vaccine Project at AIIMS, and Professor of Community Medicine said that the phone number that was issued to become volunteers for the trial has been receiving frequent calls. The way the enthusiasm of people to join this trial is being seen, it is not less than any enthusiasm for us. He said that some people have also contacted via email and WhatsApp. We try to answer everyone and we have started this work.
Meeting on human trials today
Dr. Sanjay said that after getting the approval from the committee, now our work will start from Monday. On Monday, a team meeting will be held for this trial, in which we will work on the strategy ahead. He said that we will first prepare a list of volunteers, then one by one will be called to give samples. All those who will be involved in the trial will be corona tested, only if found negative will they be included in the trial. Meaning those who have already been infected or infected will not be included. Apart from this, there will be many more types of tests, for which their blood samples will be taken. Even after all the reports are found to be correct, they will be included in the trial. Dr. Sanjay said that our effort is to start this trial in the next two to three days.
Results will take time to arrive
Dr. Sanjay said that it may take time for the results of this trial to come, as it is a two-dose schedule of Covaxin of Covid-19 prepared by ICMR and Biotech. That is, everyone will be vaccinated twice. There is a 14-day gap for this. Only then it will be known how the vaccine results on the human. He said that the good thing for AIIMS is that we have 100 out of a total of 375 subjects of the first phase trial. This is a good thing, it will increase people’s confidence.